Novel small-molecule therapeutics targeting osteoarthritis and degenerative disease
Biosplice Therapeutics (formerly Samumed) is a clinical-stage biotech developing small-molecule therapeutics that target the Wnt signaling pathway, with lead candidate lorecivivint for knee osteoarthritis. The company has not raised since 2018 and its $12.4B valuation reflects pre-Phase-III peak rather than current market pricing.
Biotech📍 San Diego, CAFounded 2008
Current Valuation
$12B
as of 2018-Q3
DECACORN
QL Price
$12B
0% vs last round
QuantLogix's current estimate for Biosplice Therapeutics, published 2026-10-07 — in line with the last disclosed round of $12B (2018-Q3).
Confidence
low
Basis
round anchored
What backs this price
Last disclosed round
$12B
2018-Q3
weight 0
How this price has held up
No round has priced for Biosplice Therapeutics since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-10-07 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Biosplice Therapeutics, 2026-10-07 (f31029f161debaed).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Biosplice Therapeutics going public?
No. Biosplice Therapeutics has no imminent IPO plans on record. It is still private.
What is Biosplice Therapeutics' valuation in 2026?
Biosplice Therapeutics is valued at $12B as of 2018-Q3, set by its Series E ($438M, Aug 2018). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Biosplice Therapeutics filed an S-1?
No public S-1 is on file for Biosplice Therapeutics.
Who are Biosplice Therapeutics' investors?
Biosplice Therapeutics' investors include Vickers Venture Partners, Hatteras Venture Partners, IKEA family office.
How much has Biosplice Therapeutics raised?
Biosplice Therapeutics has raised $650M in total, most recently a Series E of $438M in Aug 2018.
Is Biosplice Therapeutics publicly traded — can you buy Biosplice Therapeutics stock?
No. Biosplice Therapeutics is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Biosplice Therapeutics on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
CEO
Osman Kibar
Founded
2008
HQ
San Diego, CA
Employees
~250
Total Raised
$650M
Growth
The $12.4B valuation is a 2018 Samumed-era print that no later round has re-tested and that trade press has openly questioned; the company cut 41 staff and dropped its baldness program in 2022, and its value now rests on lorecivivint, the knee-osteoarthritis candidate for which it submitted an NDA to the FDA
Last Round
Series E — $438M (Aug 2018) · Lead: Vickers Venture Partners
IPO Status
no imminent plans
Fundraising Status
Series E · $438M · 8y 2mo ago
no imminent plansTotal raised $650M
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series E
$438M
Aug 2018
Vickers Venture Partners
—
Vertical Intelligence — Biotech / Gene Therapy
Registered trials
22
0 active · 0 recruiting
Lead phase
Phase 3
most advanced registered study
Focus areas
Knee Osteoarthritis
Androgenetic Alopecia · Tendinopathy
Latest trial start
2022-11-18
Name-verified against lead sponsor "Biosplice Therapeutics, Inc." on ClinicalTrials.gov as of 2026-10-04. Verify on ClinicalTrials.gov ↗
Talent Signal
No public careers page or job board could be found for Biosplice Therapeutics as of 2026-09-15. That itself is a datapoint: no open external hiring surface.
Checked the company site and major hosted job boards. Re-checked monthly.
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2018-Q3. Refreshed quarterly.